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Abstract
Introduction: Various multigene predictors of breast cancer clinical outcome have been commercialized, but
proved to be prognostic only for hormone receptor (HR) subsets overexpressing estrogen or progesterone
receptors. Hormone receptor negative (HRneg) breast cancers, particularly those lacking HER2/ErbB2 overexpression
and known as triple-negative (Tneg) cases, are heterogeneous and generally aggressive breast cancer subsets in
need of prognostic subclassification, since most early stage HRneg and Tneg breast cancer patients are cured with
conservative treatment yet invariably receive aggressive adjuvant chemotherapy.
Methods: An unbiased search for genes predictive of distant metastatic relapse was undertaken using a training
cohort of 199 node-negative, adjuvant treatment naïve HRneg (including 154 Tneg) breast cancer cases curated
from three public microarray datasets. Prognostic gene candidates were subsequently validated using a different
cohort of 75 node-negative, adjuvant naïve HRneg cases curated from three additional datasets. The HRneg/Tneg
gene signature was prognostically compared with eight other previously reported gene signatures, and evaluated
for cancer network associations by two commercial pathway analysis programs.
Results: A novel set of 14 prognostic gene candidates was identified as outcome predictors: CXCL13, CLIC5, RGS4,
RPS28, RFX7, EXOC7, HAPLN1, ZNF3, SSX3, HRBL, PRRG3, ABO, PRTN3, MATN1. A composite HRneg/Tneg gene
signature index proved more accurate than any individual candidate gene or other reported multigene predictors
in identifying cases likely to remain free of metastatic relapse. Significant positive correlations between the HRneg/
Tneg index and three independent immune-related signatures (STAT1, IFN, and IR) were observed, as were
consistent negative associations between the three immune-related signatures and five other proliferation module-
containing signatures (MS-14, ONCO-RS, GGI, CSR/wound and NKI-70). Network analysis identified 8 genes within
the HRneg/Tneg signature as being functionally linked to immune/inflammatory chemokine regulation.
Conclusions: A multigene HRneg/Tneg signature linked to immune/inflammatory cytokine regulation was
identified from pooled expression microarray data and shown to be superior to other reported gene signatures in
predicting the metastatic outcome of early stage and conservatively managed HRneg and Tneg breast cancer.
Further validation of this prognostic signature may lead to new therapeutic insights and spare many newly
diagnosed breast cancer patients the need for aggressive adjuvant chemotherapy.
Introduction
Hormone receptor-negative (HRneg) breast cancer
accounts for 30% to 40% of all newly diagnosed breast
malignancies and is clinically subdivided into either
human epidermal growth factor receptor 2 (HER2/
ERBB2)-positive or triple-negative (Tneg) breast tumors,
and about 60% of the latter consist of basal-like breast
cancers [1-4]. When characterized by histology or pro-
tein-, RNA- or DNA-based assays, HRneg and Tneg
breast cancers are consistently found to be aggressive
and heterogeneous subgroups that defy prognostic sub-
stratification [5-9]. Tneg and basal-like breast cancers
represent about 15% of all newly diagnosed breast
cancers and preferentially arise in younger women,
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Given their reputation for more invasive and prolifera-
tive characteristics, even early-stage HRneg and Tneg
breast primaries are invariably treated with adjuvant sys-
temic therapy. Since Tneg breast tumors lack clinically
validated prognostic or predictive biomarkers, their sys-
temic therapy consists of empiric combinations of toxic
chemotherapy.
The metastatic potential of HRneg and Tneg breast
cancers, unlike hormone receptor-positive (HRpos)
breast cancer, is usually manifest within 5 years of pri-
mary tumor diagnosis, with or without adjuvant che-
motherapy intervention [10-12]. For example, despite
both primary and systemic treatment, patients with
Tneg breast cancer have a median time to metastatic
recurrence of fewer than 3 years and are more than
three times as likely to die from metastases within 5
years [12]. Despite this aggressive tumor behavior, nearly
two thirds of newly diagnosed early-stage (T1,2 N0,1)
Tneg patients conservatively managed without adjuvant
chemotherapy remain disease-free 5 or more years after
diagnosis, indicating that most do not require systemic
therapy for curative intent and illustrating the clinical
heterogeneity intrinsic to this otherwise-aggressive form
of HRneg breast cancer [13]. Since more than 60% of
incident breast cancers (including HRneg and Tneg
cases) in the US are localized at the time of diagnosis
and therefore are amenable to curative management
without unnecessary systemic therapy [14], the failure of
both traditional and modern high-throughput analytical
methods to prognostically stratify HRneg and Tneg
breast cancers for more personalized and conservative
management points to a high-priority need for addi-
tional biomarker discovery [9].
Many multigene breast cancer classifiers and out-
come predictors have been introduced to date, but
none has become universally accepted, although sev-
eral have been standardized and commercialized [8,9].
Given the diversity of genes in these signatures, it is
surprising that they demonstrate nearly 80% classifi-
cation concordance with routine pathology-based
classifiers of breast cancer into HRpos, HRneg, HER2-
positive, and Tneg subgroups [9]. Owing to the pre-
dominance of HRpos breast cancers and the many
molecular differences distinguishing good-risk (lumi-
nal A) from poor-risk (luminal B) HRpos breast can-
cers, most of the well-described multigene predictors
contain gene modules known to regulate or execute
cell proliferation [9,15]. Thus, these signatures are
most effective at assigning recurrence risk to early-
stage HRpos breast cancer patients whose prognoses
can be estimated using a simple Ki67 index [15] or
more accurately assessed using a multigene predictor
enriched for regulators of DNA and cell cycle
function [16]. Large-scale meta-analyses across het-
erogeneous breast cancer datasets analyzed on differ-
ent expression microarray platforms of multigene
signatures like the 70-gene Mammaprint signature
(NKI-70) [6], Celera 14-gene metastasis score (MS-
14) [16], 76-gene Veridex signature (EMC-76) [17],
core serum response (CSR/wound) signature [18],
Oncotype/Genomic Health recurrence score (ONCO-
RS) [19], p53 [20], and genomic grade index (GGI)
[21] have shown that their prognostic values are com-
parable when evaluated against HRpos breast cancers
(with or without adjuvant treatment). Moreover,
despite the disparity in their gene composition, their
proliferation modules appear to be the common driv-
ing force behind their overall prognostic value
[22,23]. As the majority of HRneg breast cancers are
highly proliferative, these various multigene predictors
fail to show any value in discriminating prognosis
within this HR subtype, supporting the widespread
call for newer prognostic signatures not dependent on
proliferation modules [22,23].
One meta-analysis observed that higher expression of
an immune response (IR) gene module associated with
STAT1 (signal transducer and activator of transcription
1) mRNA expression was significantly associated with
better HRneg clinical outcome by univariate and multi-
variate analyses, prompting recent speculation that
impaired host IR drives the development of HRneg
metastatic events [23]. Earlier investigators showed that
a novel interferon (IFN)-regulated breast cancer gene
cluster, including the transcriptional regulator STAT1,
was associated with somewhat better prognosis cases
relative to other basal-like breast cancers [24]. Shortly
thereafter, a team employing a novel pattern recognition
and gene selection method and interrogating three pub-
lic microarray datasets (based on different platforms)
containing 186 adjuvant therapy-naïve, regionally
involved HRneg breast cancers identified a 98-gene IR
cluster and a 7-gene IR module capable of specifying up
to 25% of HRneg breast cancers (including several HER-
pos but few medullary breast cancers) with significantly
reduced risk of distant metastasis [25]. While the larger
IR-98 gene cluster contained a number of IFN-related
genes, including STAT1, the compact IR-7 module
appeared functionally related to, but prognostically dis-
tinct from, the two previously reported IFN and STAT1
gene clusters [23,24]. More recently, this IR-7 predictor
was refined by assigning different weights to the indivi-
dual genes, yielding a composite IR score whose value
increases with better HRneg prognosis [26]. While the
prognostic value of this IR score was thought to be
independent of tumor infiltration by lymphocytes [26],
high levels of lymphocyte infiltration have been found to
be associated with reduced risk of metastasis in Tneg/
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tribution of host stromal and immune cell elements
within the primary tumor remains an open question
awaiting additional study. Meanwhile, the urgency to
identify that vast majority of early-stage HRneg breast
cancer patients not destined for metastatic relapse and
to spare them unnecessary chemotherapy compelled a
subsequent unbiased microarray search among node-
negative HRneg and Tneg breast tumors for genes pre-
dictive of distant metastatic relapse.
The present study describes a novel set of 14 such
prognostic gene candidates identified from a training
cohort of 199 node-negative, adjuvant treatment-naïve
HRneg (154 Tneg) cases curated from three public
expression microarray datasets generated on the
same microarray platform. Independent validation of
the unweighted multigene HRneg/Tneg prognostic
index was performed on a different cohort of 75 node-
negative, adjuvant-naïve HRneg cases curated from
three additional public datasets generated on two dif-
ferent microarray platforms. This novel HRneg/Tneg
signature is able to better discriminate validation cases
destined for metastatic relapse in comparison with
eight other reported signatures. Interestingly, this
HRneg/Tneg multigene index lacks any proliferation
module and shows modest but significant correlations
with the previously reported IR, IFN, and STAT1 mod-
ule genes. Although the reported IR, IFN, or STAT1
module genes are not components of the HRneg/Tneg
signature, one gene component of this index (CXCL13)
correlates significantly with each of the 7 IR module
genes, indicating surrogate representation of the IR-7
module within the 14-gene HRneg/Tneg index. In
keeping with the immune ontology of both IR and
IFN/STAT1 gene signatures, network analysis of the
HRneg/Tneg signature reveals that half of the 14 index
genes are functionally linked to immune/inflammatory
cytokine regulation.
Materials and methods
Selection of HRneg and Tneg prognostic gene candidates
A set of 199 adjuvant-naïve, node-negative (N0), estro-
gen receptor-negative breast cancers annotated for dis-
tant metastasis-free survival (DMFS) was identified as
HRneg training cases from three published microarray
studies similarly analyzed on the Affymetrix (Santa
Clara, CA, USA) U133A platform ([GEO:GSE2034] [17],
[GEO:GSE5327] [28], and [GEO:GSE7390] [29]). Clinical
parameters (grade and tumor size) available from each
of these training data sources are summarized in Table
S1 in Additional file 1. Tumor HER2 status was assigned
based on mean-centered, log2-transformed ERBB2 tran-
script levels (probe set ID 216836_s_at) within each data
source, yielding 154 Tneg training cases.
For candidate discovery, an initial subset of 135
HRneg cases from [GEO:GSE2034 and GSE5327] was
analyzed by two different biostatistical approaches. In
the first, prediction analysis of microarrays (PAM) was
applied to log2-transformed discovery data subset by
data source. Approximately 300 top discriminating
probes were identified within each data source, and
common probes with PAM scores bearing the same
sign within both data sources were selected. Additional
candidates were selected on the basis of a Monte Carlo
cross-validation procedure. The discovery data subset
was Z-transformed independently within data source
and combined. A minimum variation filter was applied,
yielding approximately 14,000 probes where at least
10% of cases showed greater than twofold variation
f r o mt h em e a n .T h ef i l t e r e dd a t aw e r er a n d o m l ys u b d i -
vided into learning and test groups controlled for the
number of metastatic cases. Univariate Cox analysis
was performed, and prognostic significance was
assessed as the P value computed from the Wald sta-
tistic averaged over 100 iterations. Probes with a
P value of less than 0.01 and consistent correlation
with DMFS (that is, Cox coefficient bearing the same
sign) in more than 80% of all paired learning and test
groups over the 100 iterations were selected. Univari-
ate and multivariate Cox regression of DMFS on
Z-transformed gene expression was performed on the
discovery data for candidates with known official gene
symbol annotation identified from both approaches,
and probes with consistent correlation with DMFS in
both univariate and multivariate settings were chosen
for further assessment in the remaining 64 HRneg
training cases from [GEO:GSE7930]. Expression data
from these 64 cases were RMA-normalized and mean-
centered in Bioconductor R, and univariate Cox regres-
sion of DMFS on gene expression was performed. Can-
didates with consistent correlation with DMFS in both
subsets of the training cohort were selected as final
HRneg prognostic gene candidates for further valida-
tion. Tneg-specific prognostic gene candidates were
similarly selected from 154 Tneg training cases: 108
cases were from the initial discovery subset [GEO:
GSE2034 and GSE5237], and 46 cases were from the
additional training subset [GEO:GSE7930].
Prognostic assessment of HRneg/Tneg genes within the
training cohort
Mean-centered, log2-scaled data from the three inde-
pendent studies comprising the 199 training cases
were merged using distance-weighted discrimination
(DWD) [30]. Prognostic performance of individual
HRneg/Tneg prognostic markers was assessed using
univariate and multivariate Cox analyses as well as
Kaplan-Meier analysis of each marker dichotomized at
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H R n e g -a n dT n e g - s p e c i f i cm a r k e r sa sw e l la st h ec o m -
bined set of HRneg/Tneg markers were computed for
each patient as follows:
xx
n
i
iP
j
jN ∈∈ ∑∑ −
,
where x is the DWD-transformed expression, n is the
number of genes within the signature, and P and N are
the set of markers with positive and negative correla-
tions with increased hazard, respectively. Tumors were
dichotomized into high-versus-low index groups by
their respective indices (that is, 199 HRneg cases by
HRneg index and 154 Tneg cases by Tneg index) as
well as the combined HRneg/Tneg index using median
and upper third quartile values, which were discovered
to yield near-optimal signature performance. Kaplan-
Meier analysis was performed and significance was
assessed by the log-rank statistic. Also, Cox regression
of DMFS on group identity was performed to estimate
the hazard ratio (HR) between patient groups with high-
versus-low signature index. Candidates were also priori-
tized by stepwise variable analysis. Briefly, candidates
were added one at a time to the signature beginning
with the gene most strongly correlated with DMFS by
univariate Cox analysis (largest coefficient or minimum
P). With each step, expression indices were computed
for all possible additions and scored by univariate Cox
regression to determine the optimal order of addition
and candidate subset (largest coefficient or minimum P).
Likewise, candidates were subtracted one at a time from
the combined 14-gene HRneg/Tneg signature for priori-
tization comparison.
Prognostic assessment of HRneg/Tneg gene signature
within the validation cohort
The independent validation cohort consisted of 75
untreated, node-negative HRneg primary breast cancers
annotated for DMFS pooled from three independent
datasets ([GEO:GSE6532] [31], [EBI:E-TABM-158] [7],
and NKI-295 [32]). Clinical parameters (grade and
tumor size) available from each of these validation data
sources are summarized in Table S1 in Additional file 1.
Of these cases, 38 were analyzed on the Affymetrix plat-
form ([GEO:GSE6532], [EBI:E-TABM-158]) whereas the
remaining 37 were assayed on the Agilent Technologies,
Inc. (Santa Clara, CA, USA) HU25K platform (NKI-
295). Data generated on the Affymetrix platform were
normalized using RMA and mean-centered indepen-
dently within each data source, and Agilent data were
converted to log2-scale and mean-centered. Chip anno-
tation files were obtained from the Broad Institute
(Cambridge, MA, USA) website [33], and within each
data source, expression data were collapsed by gene
symbols such that the expression of genes represented
by multiple probes was computed as the average across
probes. Of the 14 gene candidates identified from the
Affymetrix platform-based training cohort, only one
(PRRG3) could not be identified on the Agilent array
platform. Processed expression data were mapped across
platforms using gene symbols prior to combination
using DWD. HRneg/Tneg candidates were mapped to
the combined validation dataset by gene symbol, and
prognostic performance of the HRneg/Tneg signature as
an index was assessed by Kaplan-Meier and Cox regres-
sion analyses of the validation cohort dichotomized at
the upper third quartile cut-point, which was once again
found to give near-optimal signature performance.
HRneg/Tneg signature comparisons with other multigene
predictors
The HRneg/Tneg candidates were assessed in relation to
eight other signatures: NKI-70 [6], MS-14 [16], CSR/
wound-response [18], ONCO-RS [19], GGI [21,31], IR-7
[25,26], STAT1 cluster [23], and IFN cluster [24] (Table
S2 in Additional file 2). Gene signatures were mapped
to the training and validation datasets using gene sym-
bols, and for each signature, an expression index was
computed for each patient as follows:
xx
n
i
iP
j
jN ∈∈ ∑∑ −
,
where x is the DWD-transformed expression, n is the
number of genes (within the signature) that are mapped
to the dataset, and P and N are the set of markers with
previously reported positive and negative correlations
with increased hazard, respectively. Prognostic compari-
son of the signatures was performed in the validation
cohort to avoid training bias toward the HRneg/Tneg
candidates. For each signature, tumors were dichoto-
mized into high-versus-low index groups by median
values. Here, to ensure fair comparisons and minimize
bias toward the newly identified candidates, the upper
third quartile cut-point, which yielded near-optimal
HRneg/Tneg signature performance, was not employed.
Kaplan-Meier analyses were performed and significance
was assessed by log-rank statistic. Cox regression of
DMFS on group identity was used to estimate the HR
between patient groups with high-versus-low signature
values. Pearson correlations between the signature
indices were performed using both training and valida-
tion cohorts. In addition, T cell- and B cell-specific gene
signatures derived from human peripheral blood (Table
S2 in Additional file 2) were employed to estimate the
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validation tumors [34]. Signatures were mapped to the
training and validation datasets by gene symbol, and the
average expression of each signature was computed.
Pearson correlations between the T-cell and B-cell sig-
natures and the HRneg/Tneg index and IR-7 signature
were performed on both training and validation cohorts.
To confirm these associations, the analyses were
repeated using a more restricted set of lymphocyte
genes consisting of classical T cell- and B cell-specific
surface markers and co-receptors (highlighted in red/
yellow in Table S2 in Additional file 2).
Pathway analysis of HRneg/Tneg signature genes
Pathway Studio (Ariadne Inc., Rockville, MD, USA) was
used to identify potential common upstream regulators
and downstream effectors of the Tneg/HRneg candi-
dates. Also, Ingenuity Systems (Redwood City, CA,
USA) was employed to explore potential connections
between candidates through the shortest path (at most,
one additional node) of direct interactions.
Results
Training cohort selection and assessment of HRneg/Tneg
prognostic candidates
Following the multistep protocol described in Materials
and methods, 11 probes, representing 11 unique genes
(CLIC5, CXCL13, MATN1, RPS28/ANKRD47, ABO,
E X O C 7 ,H A P L N 1 ,P R R G 3 ,P R T N 3 ,R F X D C 2 ,a n d
RGS4), were identified as HRneg prognostic candidates
from the training cohort of 199 HRneg cases. Likewise,
7 probes, representing 7 unique genes (CLIC5, CXCL13,
MATN1, RPS28/ANKRD47, HRBL, SSX3, and ZNF3),
were identified as Tneg prognostic candidates from the
subset of 154 Tneg cases within the training cohort.
Altogether, a non-redundant set of 14 genes demon-
strating prognostic value in either the full HRneg train-
ing data or the Tneg subset was identified as HRneg/
Tneg prognostic candidates (Table 1). Each of these 14
HRneg/Tneg genes showed prognostic significance by
univariate Cox analysis in the pooled training cohort,
but only half retained prognostic significance by multi-
variate analysis (Table 1). Interestingly, all but 2
(HAPLN1 and RGS4) of the 14 genes yielded negative
Cox coefficients, indicating that for the majority of the
HRneg/Tneg genes, higher transcript expression is asso-
ciated with better prognosis (Table 1). Kaplan-Meier
analysis revealed that, except for 3 genes (RPS28/
ANKRD47, MATN1, and HAPLN1), all of the HRneg
and Tneg candidates were able to dichotomize the train-
ing cohort into prognostic groups showing significant
differences in DMFS (Figures S1 and S2 in Additional
files 3 and 4).
To assess the prognostic value of these HRneg/Tneg
genes taken together as a multigene signature, an index
value was computed as the sign-corrected average
expression of the individual candidates such that higher
expression of the signature index would be expected to
correlate with worse prognosis. Kaplan-Meier analysis
revealed that index values computed from the 11 genes
identified from the HRneg training cohort (HRneg
index) or from the 7 genes identified from the Tneg
subset (Tneg index) were able to dichotomize their cor-
responding training cohorts into significantly different
DMFS outcomes using a median value cut-point (log-
rank P =2 . 0 4×1 0
-7 and 1.73 × 10
-5, respectively). The
HRneg/Tneg index, comprising the non-redundant set
of all 14 HRneg and Tneg prognostic candidates,
achieved an even more significant curve separation (log-
rank P =6 . 1 4×1 0
-8 in full training data and 1.63 × 10
-
6 in Tneg subset). Cox regression confirmed that the
hazard associated with the high 14-gene HRneg/Tneg
index value (HR 4.23, 95% confidence interval [CI] 2.4
to 7.45; P =6 . 2×1 0
-7 in full training data and HR 4.18,
95% CI 2.22 to 7.88; P =9 . 7×1 0
-6 in Tneg subset) was
greater than that associated with either the HRneg or
the Tneg indices in their corresponding training cohorts
(HR 3.93, 95% CI 2.25 to 6.86; P =1 . 4×1 0
-6 and HR
3.56, 95% CI 1.92 to 6.61; P = 5.6 × 10
-5, respectively).
Near-optimal curve separation was achieved using an
upper third quartile (≥ 75th percentile) value as an
HRneg/Tneg index cut-point (Figure 1). The Kaplan-
M e i e rc u r v e si nF i g u r e1 aa n d1 bs h o wt h ef u l lH R n e g
training cohort and its Tneg subset dichotomized at this
third quartile cut-point into groups with significantly
different DMFS outcomes based on the combined 14-
gene HRneg/Tneg signature index. The Cox propor-
tional HRs between high and low index groups were
9.13 (95% CI 5.5 to 15.2; P ~0) in the full training data
and 11 (95% CI 6.11 to 19.6; P ~0) for the Tneg subset.
As was observed using a median value cut-point, the
prognostic performance of the combined 14 gene
HRneg/Tneg index using a third quartile cut-point was
superior or comparable to that of the individual HRneg
or Tneg indices in their respective training cohorts (Fig-
ure S3 in Additional file 5).
Stepwise addition and subtraction analysis within the
199 training cohort prioritized the individual HRneg/
Tneg genes comprising the 14-gene signature and
revealed that 4 genes (CLIC5, EXOC7, RFXDC2, and
SSX3) were consistently identified as the most signifi-
cant contributors to the signature’sp r o g n o s t i cv a l u e .
Despite its prognostic significance in the multivariate
Cox analysis, HAPLN1 was identified in the stepwise
analysis as not providing additional prognostic value to
the full 14-gene HRneg/Tneg signature.
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prognostic signature
An upper third quartile cut-point for the combined
HRneg/Tneg signature index also proved near optimal
in discriminating DMFS outcome within the 75-case
validation cohort in which gene expression data were
generated from two different microarray platforms. Fig-
ure 1c shows the Kaplan-Meier curves of the validation
cohort dichotomized this way by the combined 14-gene
HRneg/Tneg index. The Cox proportional HR between
the high-versus-low HRneg/Tneg index groups in this
validation cohort was 2.85 (95% CI 1.24 to 6.52; P =
0.013).
Comparison of HRneg/Tneg signature with other
multigene predictors
To compare the prognostic value of different signatures
within the same population, a median cut-point value
was used for each signature to dichotomize the valida-
tion cohort. Kaplan-Meier comparisons revealed that, of
the nine signatures tested, only the HRneg/Tneg signa-
ture was able to significantly discriminate DMFS out-
come (Figure 2a). Proliferation module-containing
signatures like the NKI-70 (Figure 2b) and MS-14 (Fig-
ure 2c), known to be predictors of HRpos outcome
[23,24], did not produce any prognostic separation in
this HRneg population. The previously reported IR
module, IR-7, though developed as an HRneg outcome
predictor, trended toward discriminating DMFS out-
come in this HRneg population only (Figure 2d). The
log-rank P values of the Kaplan-Meier analyses and the
Cox proportional HRs between the high-versus-low
index groups for all nine multigene predictors in this
validation cohort are shown in Table 2.
All possible associations between the HRneg/Tneg
index and the eight other signatures were explored in
both the training (n = 199) and validation (n =7 5 )
cohorts (Figure 3). Signature correlations (Pearson cor-
relation coefficient, or Rp) found to be significant and
consistent between these two cohorts included the fol-
lowing: (a) positive associations between HRneg/Tneg
and three different immune-related signatures (STAT1,
IFN, and IR-7) and (b) positive associations among the
five different proliferation module-containing signatures
(MS-14, ONCO-RS, GGI, CSR/wound, and NKI-70).
Consistent negative associations between the indices of
the immune-related signatures and proliferation mod-
ule-containing signatures were observed; however, some
of these correlations did not reach significance.
To compare the relationships between the HRneg/
Tneg and IR-7 prognostic indices with the degree of
immune cell infiltration within the training and valida-
tion tumor cohorts, average expressions of T cell-specific
and B cell-specific gene signatures were computed for
each cohort. Since all of the genes in these lymphocyte-
specific signatures are positively correlated with lympho-
cyte abundance, higher lymphocyte gene signature values
within the cohorts represent higher degrees of lymphocy-
tic infiltration. Owing to sign adjustments in the calcula-
tion of the HRneg/Tneg and IR-7 prognostic indices,
Table 1 Prognostic performance of individual HRneg/Tneg gene candidates in the HRneg training cohort (n = 199)
Affymetrix ID Gene symbol Gene title Univariate Cox
analysis
Multivariate Cox
analysis
Coefficient P value Coefficient P value
204338_s_at RGS4 Regulator of G-protein signaling 4 0.24 2.64 × 10
-3 0.16 0.12
205242_at CXCL13 Chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant) -0.19 1.90 × 10
-5 -0.16 6.0 × 10
-4
205523_at HAPLN1 Hyaluronan and proteoglycan link protein 1 0.17 1.04 × 10
-3 0.18 1.4 × 10
-3
206821_x_at HRBL HIV-1 Rev binding protein-like -0.48 6.96 × 10
-4 -0.22 0.18
206904_at MATN1 Matrilin 1, cartilage matrix protein -0.50 8.97 × 10
-5 -0.11 0.45
207341_at PRTN3 Proteinase 3 (serine proteinase, neutrophil, Wegener
granulomatosis autoantigen)
-0.41 2.64 × 10
-4 -0.12 0.37
207666_x_at SSX3 Synovial sarcoma, X breakpoint 3 -0.33 2.17 × 10
-3 -0.42 5.8 × 10
-4
208902_s_at RPS28///ANKRD47 Ribosomal protein S28///Ankyrin repeat domain 47 -0.59 1.08 × 10
-3 -0.56 4.7 × 10
-3
212035_s_at EXOC7 Exocyst complex component 7 -0.58 2.47 × 10
-4 -0.42 2.4 × 10
-2
216929_x_at ABO ABO blood group (transferase A, alpha 1-3-N-
acetylgalactosaminyltransferase; transferase B, alpha
1-3-galactosyltransferase)
-0.44 3.26 × 10
-4 -0.23 9.2 × 10
-2
217628_at CLIC5 Chloride intracellular channel 5///similar to chloride
intracellular channel 5
-0.48 1.89 × 10
-4 -0.24 0.13
218430_s_at RFXDC2 Regulatory factor X domain containing 2 -0.47 2.57 × 10
-4 -0.40 4.6 × 10
-3
219605_at ZNF3 Zinc finger protein 3 -0.34 4.85 × 10
-3 -0.30 4.5 × 10
-2
220433_at PRRG3 Proline rich Gla (G-carboxyglutamic acid) 3 (transmembrane) -0.47 4.95 × 10
-4 -0.27 6.2 × 10
-2
HRneg, hormone receptor-negative; Tneg, triple-negative.
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to which these indices were derived from infiltrating T or
B lymphocytes. As shown in Table 3, modest, but signifi-
cant, negative correlations were seen between the
HRneg/Tneg index and both T-cell and B-cell gene
expressions in the training and validation cohorts. More
notably, however, the IR-7 signature correlated much
more strongly with lymphocyte-specific gene expression,
suggesting that it better reflects the extent of tumor infil-
tration by T cells and B cells whereas the HRneg/Tneg
signature likely reflects additional non-lymphocytic
tumor characteristics. Using the more restricted lympho-
cytic gene signatures containing only T- and B-cell sur-
face markers resulted in very similar correlations with
the two prognostic indices.
Pathway analysis of HRneg/Tneg index genes
Ariadne Pathway Studio analysis identified well-known
mediators of immune/inflammatory function (TNF, IL-8,
and IFN-g) and the proinflammatory cytokine/stress-acti-
vated kinase MAPK11 as potential common regulators of
4 of the 14 HRneg/Tneg index genes (Figure 4a). In
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Figure 1 Prognostic performance of the combined 14-gene HRneg/Tneg index in training and validation cohorts. Kaplan-Meier plots of
distant metastatic events dichotomized at the upper third quartile by high (red) or low (green) scores of (a) combined 14-gene HRneg/Tneg
index in the full HRneg training cohort (n = 199), (b) combined 14-gene HRneg/Tneg index in the Tneg subset of the training cohort (n = 154),
and (c) combined 14-gene HRneg/Tneg index in the full HRneg validation cohort (n = 75). Significant differences in survival between groups
were determined by log-rank analysis. DMFS, distant metastasis-free survival; HRneg, hormone receptor-negative; Tneg, triple-negative.
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Page 7 of 15addition, common downstream target analysis placed 3 of
these HRneg/Tneg genes (CXCL13, RGS4, and PRTN3)
as upstream of immune-function mediators IL-10, CCR7,
and CCL3 (Figure 4b). Additional pathway exploration
conducted using Ingenuity Pathway Systems (Figure 4c)
identified cytokine TNF as linked to 6 HRneg/Tneg
genes within a network that includes transcription factor
STAT3, a key mediator of acute-phase response. Alto-
gether, these network analyses identified 8 of the 14
genes within the HRneg/Tneg index as being potentially
linked to immune/inflammatory cytokine regulation.
Discussion
Our training (199 HRneg with 154 Tneg) and validation
(75 HRneg with 46 Tneg) cohorts of node-negative,
adjuvant treatment-naïve breast cancers showed distant
metastatic event rates similar to that of another conser-
vatively managed early-stage Tneg cohort [13]. Among
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Figure 2 Comparative prognostic performance of four different breast cancer gene signatures in the same validation cohort.K a p l a n -
Meier plot of distant metastatic events among the validation cohort of 75 HRneg cases pooled from three different sources (Materials and
methods) and dichotomized at the median signature value for high (red) or low (green) expression of the (a) HRneg/Tneg, (b) NKI-70, (c) MS-14,
and (d) IR-7 indices. Significance of the difference in survival between groups was determined by log-rank analysis. DMFS, distant metastasis-free
survival; HRneg, hormone receptor-negative; IR-7, immune response signature with 7-gene immune response module; MS-14, Celera 14-gene
metastasis score; NKI-70, 70-gene Mammaprint signature; Tneg, triple-negative.
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Page 8 of 15Table 2 Comparative prognostic performance of nine different breast cancer gene signatures in the HRneg validation
cohort (n = 75)
Breast cancer gene signatures Univariate Cox regression Kaplan-Meier analysis
Hazard ratio (95% confidence interval) P value Log-rank P value
HRneg/Tneg 2.38 (1.02-5.58) 0.045 0.039
STAT1 cluster [23] 2.06 (0.88-4.82) 0.095 0.088
IR-7 [25,26] 2.17 (0.93-5.07) 0.075 0.068
IFN cluster [24] 1.62 (0.71-3.71) 0.25 0.25
ONCO-RS [19] 1.45 (0.64-3.27) 0.37 0.36
GGI [21,31] 0.68 (0.30-1.53) 0.35 0.35
MS-14 [16] 0.84 (0.38-1.88) 0.68 0.68
NKI-70 [6] 1.33 (0.59-2.97) 0.49 0.49
CSR/wound [18] 0.68 (0.30-1.54) 0.36 0.35
CSR, core serum response; GGI, genomic grade index; HRneg, hormone receptor-negative; IFN, interferon; IR-7, immune response signature with 7-gene immune
response module; MS-14, Celera 14-gene metastasis score; NKI-70, 70-gene Mammaprint signature; ONCO-RS, Oncotype/Genomic Health recurrence score; STAT1,
signal transducer and activator of transcription 1; Tneg, triple-negative.
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Page 9 of 15Table 3 Correlations (Rp) between the HRneg/Tneg and IR-7 prognostic indices with T- and B-lymphocyte gene
signatures in the training and validation tumor cohorts
Training cohort (n = 199) Validation cohort (n = 75)
HRneg/Tneg IR-7 HRneg/Tneg IR-7
Lymphocyte-specific signatures Rp P value Rp P value Rp P value Rp P value
T-cell signature -0.31 1.18 × 10
-5 -0.65 < 2.2 × 10
-16 -0.41 2.83 × 10
-4 -0.62 3.439 × 10
-9
T-cell co-receptor components -0.39 9.28 × 10
-9 -0.73 < 2.2 × 10
-16 -0.42 1.78 × 10
-4 -0.66 7.888 × 10
-11
B-cell signature -0.33 2.74 × 10
-6 -0.89 < 2.2 × 10
-16 -0.43 1.20 × 10
-4 -0.77 9.07 × 10
-16
B-cell surface co-receptor/marker -0.15 2.94 × 10
-2 -0.63 < 2.2 × 10
-16 -0.34 2.60 × 10
-3 -0.79 < 2.2 × 10
-16
HRneg, hormone receptor-negative; IR-7, immune response signature with 7-gene immune response module; Rp, Pearson correlation coefficient; Tneg, triple-
negative.
A
HAPLN1
SP1
PRTN3
ABO
CXCL13
TNF IFNG
MAPK11
IL8
RGS4
+ +
+
+
+
+
B
CXCL13
RGS4
PRTN3
MAPK1 AKT1 IL10 CCL3 CCR7
+
+
+
+
+
+
STAT3
RPS28
ACTA1
RGS4
CLIC5
CXCL13
TNF
EXOC7
FN1
GTP
EEF1G
PRTN3 C
Figure 4 Functional network connections between HRneg/Tneg signature genes. (a) Pathway diagram linking HRneg/Tneg genes with
common upstream regulators. (b) Pathway diagram linking HRneg/Tneg genes with common downstream effectors. (c) Pathway diagram
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Page 10 of 15the training set, 65 (33%) had an eventual metastatic
relapse and 85% of these occurred within 5 years of
diagnosis; among the validation set, 24 (32%) had a
metastatic event, and 91% of these occurred within
5 years of diagnosis. Given this clinical behavior and the
77% preponderance of Tneg primary tumors in the
training set, it may not be surprising that of the 11 top
prognostic candidates entrained by the full HRneg
cohort, four genes (CXCL13, CLIC5, RPS28, and
MATN1) were also among the 7 top prognostic candi-
dates independently entrained by the 154 Tneg tumors.
The slightly different prognostic performances of indivi-
dual genes within each training set are illustrated by
CLIC5, MATN1, and RPS28, which were slightly more
effective discriminators against the Tneg subset relative
to the full set of HRneg tumors (Figures S1 and S2 in
Additional files 3 and 4). It is interesting to note that
higher expression of 12 of the 14 HRneg/Tneg genes is
associated with better DMFS. This is consistent with
observations among other HRneg outcome predictors
(IR-7, STAT1, and IFN signatures) in which individual
gene components are often more highly expressed in
association with better prognosis [23-26], and this is in
stark contrast with HRpos outcome predictors, in which
elevated expression of the majority of gene components
is associated with increased tumor proliferation and
poor prognosis [22,23]. These inherent differences were
taken into account during the computation of a compo-
site signature index, such that a higher index value
would be expected to correlate with worse DMFS
outcome.
Relative to their gene-specific prognostic values, a com-
posite signature score (index) based on all of the candi-
date genes proved to be a better discriminator of
metastatic outcome. Despite their variable Cox coeffi-
cients, no attempt was made to individually weight each
gene in generating the index. While indices computed
f r o mt h eH R n e ga n dT n e gg e n e sa l o n ew e r ea b l et o
dichotomize their respective training cohorts into groups
with significant differences in DMFS (Figure S3 in Addi-
tional file 5), a combined index comprising all 14 HRneg/
Tneg genes was able to achieve equivalent or better
curve separation at both cut-points tested, thus providing
a rationale for considering all 14 HRneg/Tneg genes
together as a signature in further studies. Stepwise vari-
able addition and removal analysis identified candidate
subsets from which indices can be computed without
loss of prognostic performance as assessed by univariate
Cox analysis, suggesting that the HRneg/Tneg signature
index has prognostic robustness. In particular, when the
training cohort was dichotomized at a median value cut-
point, the removal of up to three genes (for example,
SSX3, MATN1, and PRTN3) did not significantly alter
the HRs between poor versus good prognosis groups
calculated from the modified 11-gene index relative to
the full 14-gene index (HR 3.6, 95% CI 2.07 to 6.26 and
HR 4.23, 95% CI 2.4 to 7.45, respectively). Also, a trun-
cated index consisting of only 7 selected genes (CXCL13,
CLIC5, RGS4, RPS28, RFX7, EXOC7, and HRBL) mini-
mally altered the Kaplan-Meier curves and did not signif-
icantly reduce the HR (HR 3.6, 95% CI 2.09 to 6.23).
Since both training and validation cohorts were com-
posed of cases clinically annotated as HRneg, we reas-
sessed the prognostic performance of the HRneg/Tneg
index after removing 35 HRneg cases from the training
cohort and 11 cases from the validation cohort having
potentially high enough estrogen receptor transcript
levels to be considered potentially false HRneg annota-
tions. After these adjustments were made, the prognostic
value of the HRneg/Tneg index improved slightly, as
seen in the adjusted HRs calculated for the median cut-
point dichotomized training and validation groups
(HR 4.57, 95% CI 2.45 to 8.54 and HR 2.72, 95% CI 1.11
to 6.67, respectively).
Choice of cut-points may significantly influence a sig-
nature’s prognostic performance. Thus, although signifi-
cant curve separation was achieved in the full training
data (and the Tneg subset) using the median index value
as a cut-point, additional Kaplan-Meier analyses were
conducted to identify an optimal cut-point that mini-
mizes the log-rank P value. Care was taken to restrict
these analyses to cut-points within the 20th and 80th
percentiles to prevent extreme group sizes and reduce
the likelihood of over-fitting the training data. Optimal
curve separations were achieved at cut-points near the
upper third quartile for the HRneg and Tneg indices in
their respective training cohorts as well as the 14-gene
HRneg/Tneg index in the full training data and the Tneg
subset, suggesting that selecting an upper third quartile
cut-point in future studies may yield optimal signature
performance. This observation was independently con-
firmed in the validation cohort whose gene expression
data were derived from two different expression microar-
ray platforms; here, optimal curve separation was
observed at an index value of 0.2087 and very close to
the upper third quartile (0.2388). Interestingly, despite
placing 75% of patients in the good-prognosis group,
when accuracy was assessed as a function of the propor-
tion of metastatic events based on high or low index
values, the HRneg/Tneg index appeared highly accurate
at identifying patients with good prognosis and less accu-
rate at assigning patients to the poor-prognosis category,
consistent with previous observations showing better
negative predictive value and less-optimal positive pre-
dictive value for the IR gene signature [26]. These perfor-
mance characteristics suggest that the HRneg/Tneg
index may be well suited for identifying newly diagnosed,
early-stage patients whose expected good outcome on
Yau et al. Breast Cancer Research 2010, 12:R85
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Page 11 of 15conservative management would not mandate aggressive
adjuvant chemotherapy. To explore this possibility
further, we considered the distribution of HRneg/Tneg
indices within the training and validation cohorts for
those with either metastatic or non-metastatic outcomes
(Figure S4 in Additional file 6); these distributions indi-
cate that 10% to 15% of these cohorts have tumors with
very low HRneg/Tneg indices and less than 10% likeli-
hood of metastatic recurrence. However, additional inde-
pendent validation studies are needed to confirm the
presence of this small subgroup, which was not detected
by the current optimization protocol and its survival
characteristics.
The prognostic performance of the HRneg/Tneg index
was also compared with that of other well-validated mul-
tigene predictors (Figure 2); in addition, the multiple pre-
dictive indices were compared with one another across
both the training and validation cohorts (Figure 3). Non-
optimized median values were used as cut-points for
prognostic comparison purposes in the validation dataset
to minimize bias toward the HRneg/Tneg signature.
Despite these measures, only the HRneg/Tneg index
demonstrated significant Kaplan-Meier curve separation,
whereas the previously reported IR signature and two
other immune-related signatures approached significance
in our pooled validation cohort only. This is in contrast
to signatures like ONCO-RS and MS-14 that were origin-
ally developed as HRpos outcome predictors and showed
no prognostic value within this HRneg cohort and is in
agreement with previous reports suggesting that prog-
noses of HRneg and HRpos breast cancers are driven by
fundamentally different mechanisms [22,23]. While the
strong correlations between different proliferation mod-
ule-containing signatures were expected and in keeping
with previous reports (as were the significant associations
between the different immune-related signatures), the
anti-correlations observed between the composite scores
(index) of proliferation and immune signatures in HRneg
breast cancers were not previously noted. It is worth not-
ing that, owing to the adjustments made during index
computations, these anti-correlations reflect a positive
association between immune and proliferation function
and may be in keeping with the growth-stimulatory
effects of proinflammatory cytokine/chemokine signaling.
These anti-correlations may also be attributed in part to
the poor prognostic performances of proliferation mod-
ule-containing signatures in HRneg breast cancers and
may account for the lack of prognostic value of the
HRneg/Tneg and IR signatures within a corresponding
cohort of more than 400 node-negative, adjuvant-naïve
HRpos breast cancers ([GEO:GSE2034, GSE7390], NKI-
295) in which both the ONCO-RS and MS-14 signatures
are significantly prognostic (data not shown).
Given these signature associations, it is not entirely
surprising that network analysis of the HRneg/Tneg sig-
nature employing two different commercial pathway
programs revealed no links to known proliferation path-
ways but showed direct and indirect connections to sev-
eral immune/inflammatory nodes, with 8 of the 14
HRneg/Tneg signature genes functionally linked to che-
mokine regulation and expression (Figure 4). Although
the IR, IFN, and STAT1 signature genes are not compo-
nents of the HRneg/Tneg signature, one gene in this
index, CXCL13, was found to correlate significantly with
each of the 7 IR genes, suggesting surrogate representa-
tion of the IR-7 index within the HRneg/Tneg signature
and probably accounting for the weak but consistent
association observed between the HRneg/Tneg index
and the three other immune-related signatures in both
training and validation cohorts. The observation that
these three other immune-related signatures correlated
much more strongly among themselves supports
the possibility that the 14-gene HRneg/Tneg signature
contains other non-immune/inflammatory modules,
although examples of such pathways were not apparent
in our network analysis. To pursue this hypothesis
further, we attempted to correlate both the HRneg/Tneg
and IR-7 indices with an assessment of lymphocyte infil-
tration within the cohort tumors. Only a small subset of
the dataset tumors was clinically annotated for degree of
lymphocytic infiltration [6,29], and an initial analysis of
these few Tneg cases suggested a possible trend between
the HRneg/Tneg score and the degree of lymphocytic
infiltration (data not shown). Therefore, using a reported
set of T cell- and B cell-specific genes as surrogate sig-
natures for lymphocytic infiltration in the training and
validation cases (Table S2 in Additional file 2) [34], we
demonstrated a modest correlation between the HRneg/
Tneg index and both T-cell and B-cell gene expression.
By comparison (Table 3), the IR-7 index correlated
much more strongly with these lymphocyte-specific
gene expression signatures, indicating that the IR-7
index may largely represent the extent of tumor infiltra-
tion by T cells and B cells and the HRneg/Tneg index
potentially reflects this as well as additional tumor
epithelial characteristics.
Of the chemokine-associated genes in the HRneg/
Tneg index, CXCL13 (ligand for the chemokine receptor
CXCR5) has been best studied in breast cancer and
recently was shown to be the most significantly overex-
p r e s s e d( m R N Aa n dp r o t e i n )c h e m o k i n ei nap a n e lo f
early-stage human breast cancers following a survey of
84 different chemokines [35]. Surprisingly, in this study,
breast cancer overexpression of CXCL13 did not corre-
late with tumor infiltration by leukocytes but instead
was immunohistochemically localized to the cytoplasm
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illustrates the possibility that some HRneg/Tneg signa-
ture genes emerge as blood biomarkers since CXCL13
blood levels were found to be specifically increased in
patients with breast cancer [35]. Another chemokine-
associated HRneg/Tneg gene initially thought to be
expressed only in activated neutrophils, PRTN3 (neutro-
phil-derived serine proteinase 3), was recently shown to
be transcriptionally overexpressed in cytokine-exposed
epithelial cells, although its expression has not yet been
linked to cancer [36,37]. Other chemokine-associated
genes in the HRneg/Tneg signature linked to both
epithelial and cancer cell expression include EXOC7
(exocyst complex component 7) [38], ABO (blood group
glycosylransferases A and B) [39], CLIC5 (chloride intra-
cellular channel 5) [40], RPS28 (40S ribosomal protein
S28) [41], HAPLN1 (hyaluronan- and proteoglycan-
linked protein 1) [42], and RGS4 (regulator of G-protein
signaling 4) [43-46]. Studies of the last gene also illus-
trate why transcriptome-derived cancer signatures
cannot reliably be extrapolated to protein-based tumori-
genic mechanisms without more in-depth evaluation.
While RGS4 transcriptional upregulation has been asso-
ciated with increased viability, invasion, and motility of
thyroid cancer, glioma, ovarian ascites, and Tneg breast
cancer cells, it has now been shown that RGS4 mRNA
and protein levels do not correlate, since (despite high
RGS4 transcript levels) RGS4 protein levels must be
proteasomally downregulated to enable metastasis [46].
To date, none of the 6 other HRneg/Tneg signature
genes not functionally linked to chemokine pathways
(PRRG3, RFX7, MATN1, SSX3, HRBL, and ZNF3) has
shown any reported association with cancer.
Conclusions
A 14-gene HRneg/Tneg prognostic signature was identi-
fied from pooled expression microarray data from
HRneg and Tneg breast cancer cases (node-negative,
adjuvant-naïve) assigned for signature training (n = 199
cases) and validation (n = 75 cases). In both pooled
cohorts, the HRneg/Tneg summation index proved
prognostically superior to a recently described IR-7 gene
signature derived from different HRneg training and
validation cases, although expression of one gene in the
HRneg/Tneg signature (CXCL13) appears to correlate
with all components in the IR-7 signature, which, in
turn, correlates strongly with other reported immune-
related gene signatures and the extent of tumor infiltra-
tion by lymphocytes. In contrast, previously described
multigene predictors known to contain proliferation
modules are shown to have no prognostic value in these
HRneg and Tneg breast cancer cohorts. Over half of the
genes in the HRneg/Tneg prognostic signature show
network and pathway links to chemokine expression;
however, the HRneg/Tneg index may reflect both
immune cell infiltration as well as tumor epithelial char-
acteristics since many of the signature-associated che-
mokines are known to be expressed by epithelial cells.
Further validation of this HRneg/Tneg prognostic signa-
ture is now in progress following transfer to a different
assay platform (reverse transcription-polymerase chain
reaction) suitable for use on archived and clinical sam-
ples of formalin-fixed and paraffin-embedded breast
cancers.
Additional material
Additional file 1: Supplemental table S1. Summary of patient
characteristics (grade, tumor size and number of samples scored for
lymphocytic infiltration) by data source. “na” denotes where this
annotation is not available to the public; and “nd” represents cohorts
where Tneg status by ERBB2 transcript levels were not determined.
Additional file 2: Supplemental table S2. Established multigene
signatures assessed in comparison to HRneg/Tneg signatures. Signatures
annotated for Affymetrix probe set information (STAT1 and GGI) are
mapped to training data using the Affymetrix probe set ID; otherwise,
signatures are mapped using gene symbols. Only signature components
that can be mapped (as denoted by a “Y” in the “Mapped to Training
Set” or “Mapped to Validation Set” columns) are included in the
computation of signature indices in accordance to their reported
correlation with prognosis (as denoted in the “Contribution to Index”
column).
Additional file 3: Supplemental figure S1. Prognostic performance of
individual HRneg genes in training cohort. Kaplan-Meier plots of distant
metastatic events dichotomized at the median by high (red) or low
(green) expression of individual HRneg genes in training cohort of 199
HRneg cases. Significant differences in survival between groups were
determined by log rank analysis.
Additional file 4: Supplemental figure S2. Prognostic performance of
individual Tneg genes in training cohort. Kaplan-Meier plots of distant
metastatic events dichotomized at the median by high (red) or low
(green) expression of individual Tneg genes in training cohort subset of
154 Tneg cases. Significant differences in survival between groups were
determined by log rank analysis.
Additional file 5: Supplemental figure S3. Prognostic performance of
the 11-gene HRneg and 7-gene Tneg indices considered independently.
Kaplan-Meier plots of distant-metastatic events dichotomized at the
upper 3
rd quartile by high (red) or low (green) expression indices of (A)
the 11 prognostic gene candidates identified from the 199 HRneg
training cases; and (B) the 7 prognostic gene candidates identified from
the subset of 154 Tneg training cases.
Additional file 6: Supplemental figure S4. Distribution of HRneg/Tneg
scores by cohort and outcome. The histograms of HRneg/Tneg scores
among cases with metastatic (red) or non-metastatic (blue) outcome
within the (A) training and (B) validation cohorts. Red dotted-line boxes
labeled “worst prognosis group” highlight cases within the upper 3
rd
quartile of HRneg/Tneg scores, corresponding to the “High” index groups
shown in Figures 1A and 1C. Green dotted-line boxes labeled ‘best
prognosis group’ highlight cases with very low index values (lowest
~15% in training, and ~11% in validation cohorts) with better than 90%
DMFS.
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